CompletedNot Applicable

The Molecular Mechanism of RAS Wild-type mCRC Resistance to Anti-EGFR-antibody

China40 participantsStarted 2017-03-01

Plain-language summary

Establishing the genetic map of primary and secondary resistance of Chinese wild RAS colorectal cancer received anti-EGFR treatment through tissues and peripheral blood NGS testing. Combination genetic data with clinical characteristics, prognosis and treatment data to explore the molecular mechanism of resistance of anti-EGFR-antibody.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age≥18 years, ≤75 years, all gender;
✓. Histologically proven metastatic adenocarcinoma of colorectal cancer, no previous history of cancer;
✓. The clinical data of patient is intact;
✓. The data of patients after surgery is intact, and the prognosis follow-up data of patient is available.

Exclusion criteria

✕. Previous history of cancer；
✕. Intact clinical data or diagnosis results of histopathology is unavailable;
✕. Time of progression disease after treatment and follow-up data are unavailable;
✕. Patient received blood transfusion within 3 months;
✕. Other situation that researchers think it will impact the results of trails or violate ethics.

What they're measuring

The molecular mechanism of patients primary or secondary resistance to cetuximab

Timeframe: up to 36 months

Trial details

NCT IDNCT04466267

SponsorSun Yat-sen University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-03-01

View on ClinicalTrials.gov More Colorectal Cancer trials